QURE
|Uniqure NV
NASDAQ
USD 15.07
-0.09|-0.59%
Current Price
USD 15.07
Change
USD -0.09 (-0.59%)
P/E Ratio
Dividend Yield
Market Cap
823.42M
Volume
266,459
Open
USD 15.19
Previous Close
USD 15.16
52-Week High
USD 19.18
52-Week Low
USD 3.73
About Uniqure NV
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial t...
Sector:Healthcare
Industry:Biotechnology
CEO:Mr. Matthew Craig Kapusta CPA
Employees:209
Headquarters:Amsterdam, Netherlands
Website:www.uniqure.com
Dividend History
Dividend Payments
| Declared Date | Record Date | Payment Date | Amount | Frequency |
|---|
Similar Companies
Explore Stocks by Sector
technology
finance
healthcare
Frequently Asked Questions